Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort - PubMed
3 hours ago
- #statins
- #secondary prevention
- #diabetes risk
- Statins, crucial for secondary prevention in ASCVD, may increase risk of new-onset diabetes (NODM), with varying risks among specific statins.
- Study of 29,826 Korean patients with ASCVD initiating statin therapy found 40% developed NODM over five years; incidence was similar between high- and moderate-intensity statins.
- Among moderate-intensity statins, rosuvastatin, pravastatin, and simvastatin showed higher NODM risk compared to atorvastatin, while fluvastatin and pitavastatin had no significant difference.
- Major adverse cardiac and cerebrovascular events (MACCE) incidence did not differ across statins, suggesting comparable cardiovascular outcomes.
- Findings indicate statin-induced diabetes risk is agent-specific, not a uniform class effect, emphasizing the need for personalized statin selection to balance metabolic and cardiovascular benefits.